Current Affairs - Science - Discussion

AdFalciVax is India’s first indigenous recombinant chimeric malaria vaccine candidate, designed to combat the deadly Plasmodium falciparum parasite. It is a multi-stage vaccine that targets two critical stages of the parasite’s life cycle, enhancing its effectiveness against malaria. Developed through a collaborative effort between the Indian Council of Medical Research (ICMR) and the Department of Biotechnology–National Institute of Immunology (DBT–NII), this innovative vaccine represents a significant milestone in India’s public health and biomedical research initiatives. AdFalciVax reflects the country’s growing capabilities in tackling infectious diseases through indigenous scientific advancements.